

Comparison energy transfer Tixel vs. IPL*

Tixel C
Energy
J/CM²

0,012

IPL*
Energy
J/CM²

12

* source: IOVS journal (March 2015):

Prospective Trial of Intense Pulsed Light
for the Treatment of Meibomian
Gland Dysfunction



Novoxel® GmbH

Gatower Str. 124
13595 Berlin, Germany

Tel.: +49 (0) 30 - 54 81 11 95

Fax: +49 (0) 30 - 54 81 69 51

Email: info@novoxel.com

www.novoxel.com

Customer Support

Tel.: +49 (0) 30 - 54 81 11 95

Email: supportGmbH@novoxel.com



Non-radiation technology
for safe dry eye treatment



Novoxel, Tixel, their logos and product designs are registered
trademarks of Novoxel Ltd.

Product specifications are subject to change without notice.
Products are not for sale in the US and Canada.

Patented in USA, Israel, Japan; Pending in EU, South Korea and China.

What is „Tixel C“ ?

- A novel non-ablative fractional system powered by Novoxel's patented titanium tip technology.
- „Tixel C“ employs direct heat and is radiation-free.




Why „Tixel C“ ?

- Non-radiation technology – safer for retina
- Controlled direct surface heating by conduction
- Simultaneous heating and mechanical compression directly on glands
- Precise small dimensions tip, well defined locus heating
- Significantly reduced energy transfer compared to IPL
- Sterile tip prevents cross contamination of treated sites
- Superior and lower eye lids can be treated safely
- Quick (20 pulses, less than 1 minute per eye)


Improvement of NBUT & OSDI after „Tixel C“

source: Vallmedic Vision, Andorra
77 patient study

Improvement of NBUT after Tixel treatment $P < 0.05$




Before treatment



Non invasive first
Breakup time
(NIF-BUT): 3,8 sec

After 2 treatments



Non invasive average
Breakup time
(NIAvg-BUT): 7,6 sec

Improvement of OSDI-results after treatment with Tixel (% of patients)

